# US 2010/0167987 A9 · Methods and pharmaceutical compositions for healing wounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167987 A9
- Document ID: US20100167987A9
- Status: Published application
- Kind: A9
- Application number: 12/404,622
- Filed: 2009-03-16
- Published: 2010-07-01
- Earliest claimed: 2000-07-31
- Assignees: Bar-Ilan University
- Inventors: Tamar Tennenbaum; Sanford Sampson; Toshio Kuroki; Addy Alt; Shlomzion Shen
- Web page: https://patentgrep.com/patent/US20100167987A9

## CPC

- A61K 31/785: Polymers containing nitrogen
- A61K 31/74: Synthetic polymeric materials
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/28: Insulins
- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61K 38/45: Transferases (2)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 15/02: for disorders of the vagina
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 27/02: Ophthalmic agents
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2799/022: where the vector is derived from an adenovirus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound.

## Claims

### Claim at position 1

1-111. (canceled)

### Claim 112

A pharmaceutical composition comprising a single dose-unit of insulin and a pharmaceutically acceptable carrier, wherein the single dose-unit comprises a sufficient amount of said insulin to induce or accelerate a healing process of the skin wound in a subject.

### Claim 113 (depends on 112)

The pharmaceutical composition of claim 112, wherein said pharmaceutical composition is for topical administration.

### Claim 114 (depends on 112)

The pharmaceutical composition of claim 112, wherein said insulin is recombinant.

### Claim 115 (depends on 112)

The pharmaceutical composition of claim 112, wherein said insulin is from a natural source.

### Claim 116 (depends on 112)

The pharmaceutical composition of claim 112, wherein the formulation is an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve or an ointment.

### Claim 117

A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition comprising insulin, a myristoylated PKCalpha inhibitor peptide, and a pharmaceutically acceptable carrier.

### Claim 118

A pharmaceutical composition for inducing or accelerating a healing process of a skin wound, the pharmaceutical composition consisting of insulin, a myristoylated PKCalpha inhibitor, and a pharmaceutically acceptable carrier.
